Trajan Scientific Acquires LEAP Technolgies
Trajan Scientific and Medical (Melbourne, Australia) has announced the acquisition of LEAP Technologies Inc. (Carrboro, North Carolina, USA).
Trajan Scientific and Medical (Melbourne, Australia) has announced the acquisition of LEAP Technologies Inc. (Carrboro, North Carolina, USA). Both Trajan Scientific and LEAP Technologies expressed their excitement over the deal and highlighted the positive vision both companies hold towards improving not only lab efficiencies but also human wellbeing.
Stephen Tomisich, Chief Executive Officer of Trajan, said, “We are so pleased to welcome the LEAP team into the Trajan family. Trajan has a technology-rich development pipeline of disruptive sampling and sample preparation products speeding towards commercialization and LEAP provides the automation capability to allow adoption into laboratory workflows. We think it’s a partnership with huge potential!”
Trajan, a developer of medical devices as well as analytical systems, was founded in 2011 and quickly expanded into European, American, and Asian markets. LEAP Technologies was formed in 1989 to serve the automation needs of analytical laboratories and deliver solutions for separations scientists across multiple areas of research.
“The opportunity for LEAP to join Trajan will be a tremendous step forward to best apply new automation configurations for the fast evolving analytical chemistry laboratories worldwide. The synergies are multiple and can speed up the positive impact on human wellbeing by improving developments for laboratory automation and workflow,” stated Werner Martin, President of LEAP Technologies.
The deal offers opportunities for both companies as they seek to improve their product offerings and innovate new technologies for the analytical science and diagnostic markets.
For more information please visit: http://www.trajanscimed.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
